Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Hematinics

All Drugs and Chemicals

Liver Extracts

irreversible electroporation

nanoknife AngioDynamics US Ltd

Kai-Wen Huang, PhD

Liver cancer including primary hepatocellular carcinoma (HCC) and metastatic liver cancers is one the most common malignancies in the world. Over 10000 new cases per year are diagnosed in Taiwan. Despite the many treatment options, the prognosis of HCC remains dismal. More than 8000 people died of this cancer every year in Taiwan. A majority (70%to 85%) of patients present with advanced or unresectable disease. In contrast, small liver cancers can be cured with an appreciable frequency. Five-year disease-free survival exceeding 50% has been reported for surgical resection, and for the inoperable patients who do not have vascular invasion or extrahepatic spread. Radiofrequency ablation (RFA) is recommended as an alternative curative therapy. However, the main drawback of RFA is its limitation to tumor size and location. The tumors larger than 5 cm in diameter or located adjacent to vessels, could not be ablated completely.

Irreversible electroporation (IRE), developed and manufactured by AngioDynamics US Ltd, can ablate tumor by fenestrating the cancer cell membrane by electric pulse. The anti-tumor effect does not result from thermotherapy, so is also not diminished by adjacent vessels. Several pre-clinical studies have already demonstrated IRE is a safe and effective treatment for live cancers. The system has received CE mark approval in 2008 and FDA approval in 2010. However, there is no experience in using IRE fro tumor ablation in Taiwan. In this study, the investigators will perform intraoperative IRE for the patients with liver cancers who are scheduled to receive hepatectomy in our hospital, and the investigators will evaluate the ablate effect of tumors on specimens, and the effect of adjacent vessels. The investigators will appraisal the clinical feasibility and advantage of the system by this study.

Evaluation of Tumor Ablation Effects by Irreversible Electroporation for Patients With Malignant Liver Tumors

National Taiwan University Hospital

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Evaluation of Tumor Ablation Effects by Irreversible Electroporation for Patients With Malignant Liver Tumors	NCT02010801	Malignant Liver...	irreversible el... nanoknife Angio...	18 Years -	National Taiwan University Hospital
Evaluation of Tumor Ablation Effects by Irreversible Electroporation for Patients With Malignant Liver Tumors	NCT02010801	Malignant Liver...	irreversible el... nanoknife Angio...	18 Years -	National Taiwan University Hospital
Evaluation of Tumor Ablation Effects by Irreversible Electroporation for Patients With Malignant Liver Tumors	NCT02010801	Malignant Liver...	irreversible el... nanoknife Angio...	18 Years -	National Taiwan University Hospital

Spots Global Cancer Trial Database for nanoknife angiodynamics us ltd